Pulike Biological Engineering, Inc. Class A

Pulike Biological Engineering, Inc. Class A

SSSE:603566
9.05
CNY
-0.04
(-0.44%)
0.25EPS
32.54P/E
3.54BMarket Cap
Apr 23Next Earn

Total Valuation

CNY

As of September 30, 2026, Pulike Biological Engineering, Inc. Class A carries a market capitalization of 3.54B, placing it among publicly traded companies globally. Its enterprise value stands at 2.88B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.54B
Enterprise Value2.88B

Important Dates

Pulike Biological Engineering, Inc. Class A's next confirmed earnings release is scheduled for April 23, 2027.

Earnings Date4/23/2027

Share Statistics

As of September 30, 2026, Pulike Biological Engineering, Inc. Class A has 346.06M shares outstanding.

Shares Outstanding346.06M

Valuation Ratios

As of September 30, 2026, Pulike Biological Engineering, Inc. Class A trades at a trailing price-to-earnings ratio of 32.54. The price-to-sales ratio is 3.48, and the price-to-book ratio stands at 1.39.

PE Ratio32.54
PS Ratio3.48
PB Ratio1.39
P/TBV Ratio1.60

Enterprise Valuation

As of September 30, 2026, Pulike Biological Engineering, Inc. Class A trades at an EV/EBITDA multiple of 29.72 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.86 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 29.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.88B versus a market cap of 3.54B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.86
EV / EBITDA29.72
EV / EBIT29.72

Financial Position

As of September 30, 2026, Pulike Biological Engineering, Inc. Class A maintains a current ratio of 3.72, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.96, indicating moderate leverage, while an interest coverage ratio of 157.26 demonstrates strong ability to service its debt obligations.

Current Ratio3.72
Quick Ratio2.11
Debt / Equity0.96
Debt / EBITDA0.26
Interest Coverage157.26

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Pulike Biological Engineering, Inc. Class A posted a return on equity (ROE) of 4.17, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 3.22 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.49, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.95, useful for judging operating efficiency across full business cycles. The company generates approximately 661,561.23 in revenue per employee across its workforce of 1,519.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.31 indicates how many times Pulike Biological Engineering, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)4.17
Return on Assets (ROA)3.49
Return on Invested Capital (ROIC)3.22
Return on Capital Employed (ROCE)4.95
Revenue Per Employee661,561.23
Employee Count1,519.00
Inventory Turnover2.31

Taxes

CNY

Over the twelve months ended September 30, 2026, Pulike Biological Engineering, Inc. Class A recorded 11.24M in income tax expense. That works out to an effective tax rate of 11.74, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 95.69M, leaving 107.40M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax11.24M
Effective Tax Rate11.74

Stock Price Statistics

CNY

As of the close on November 17, 2026, Pulike Biological Engineering, Inc. Class A's stock has declined approximately 36.49% over the past 52 weeks. The 50-day moving average sits at 9.95, while the 200-day moving average is 11.30.

52-Week Price Change-36.49%
50-Day Moving Average9.95
200-Day Moving Average11.30

Income Statement

CNY

Over the twelve months ended September 30, 2026, Pulike Biological Engineering, Inc. Class A generated 1.00B in revenue and converted that into 107.40M in net income, yielding earnings per share of 0.25. EBITDA reached 96.79M, while operating income came in at 103.29M.

Revenue1.00B
Gross Profit564.84M
Operating Income103.29M
Pretax Income95.69M
Net Income107.40M
EBITDA96.79M
EBIT96.79M
Earnings Per Share (EPS)0.25

Balance Sheet

CNY

As of September 30, 2026, Pulike Biological Engineering, Inc. Class A holds 800.75M in cash and equivalents against 25.52M in total debt, resulting in a net debt position of -236.62M. Total book value stands at 2.55B, with working capital of 1.03B providing operational flexibility.

Cash & Cash Equivalents800.75M
Total Debt25.52M
Net Debt-236.62M
Equity (Book Value)2.55B
Book Value Per Share7.36
Working Capital1.03B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-60.79M

Margins

Over the twelve months ended September 30, 2026, Pulike Biological Engineering, Inc. Class A posted a gross margin of 56.21, reflecting its pricing power and cost economics. The operating margin of 10.28 and net profit margin of 10.69 provide insight into operational efficiency.

Gross Margin56.21
Operating Margin10.28
Pretax Margin9.52
Profit Margin10.69
EBITDA Margin9.63

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Pulike Biological Engineering, Inc. Class A paid dividends of 0.60 per share. The dividend payout ratio of 334.48 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 5.85, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Pulike Biological Engineering, Inc. Class A shareholders.

Dividend Per Share0.60
Payout Ratio334.48
Shareholder Yield5.85

Stock Splits

Pulike Biological Engineering, Inc. Class A's most recent stock split took place on May 31, 2016 with a 1:2 split ratio.

Last Split Date5/31/2016
Split Ratio1:2

Scores

As of September 30, 2026, Pulike Biological Engineering, Inc. Class A has an Altman Z-Score of 6.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.18